Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

8.9K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.9K
Types of RNA01:20

Types of RNA

6.3K
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in regulating gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA Performs Diverse...
6.3K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

17.0K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
17.0K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

30
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
30
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

32
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
32

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Lineage-restricted dependency on an oncofetal SNHG29-IGF2BP1 RNA axis in acute megakaryoblastic leukemia.

Leukemia·2026
Same author

Pharmacological clearance of senescent cells reduces inflammation, endothelial damage and cardiac fibrosis in HFpEF.

Cardiovascular research·2025
Same author

An interplay of non-coding RNAs regulates <i>CDH13</i> expression and affects endothelial function and coronary artery disease risk.

Research square·2025
Same author

Aging-regulated PNUTS maintains endothelial barrier function via SEMA3B suppression.

Communications biology·2024
Same author

DLC1 promotes mechanotransductive feedback for YAP via RhoGAP-mediated focal adhesion turnover.

Journal of cell science·2024
Same author

HDAC1/2 inhibitor therapy improves multiple organ systems in aged mice.

iScience·2024

Video Experimental Relacionado

Updated: Sep 9, 2025

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model
06:03

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model

Published on: June 11, 2020

9.2K

Terapia basada en ARN largo no codificante para enfermedades cardiovasculares

Noelia Bellon Quinones1,2, Ruggero Belluomo3,4, Rio P Juni5,6

  • 1Institute for Cardiovascular Regeneration, Centre for Molecular Medicine, Goethe University, Frankfurt Am Main, Germany.

Journal of cardiovascular translational research
|September 3, 2025
PubMed
Resumen

Los ARN largos no codificantes (ARNlnc) son reguladores clave en las enfermedades cardiovasculares (ECV). La investigación destaca su potencial como biomarcadores y objetivos terapéuticos, con terapias génicas avanzadas que son prometedoras para tratamientos futuros.

Palabras clave:
Enfermedades cardiovascularesTerapia génicaARN largos no codificantes (ARNl)Terapia con ARN

Más Videos Relacionados

Overexpressing Long Noncoding RNAs Using Gene-activating CRISPR
13:04

Overexpressing Long Noncoding RNAs Using Gene-activating CRISPR

Published on: March 1, 2019

9.0K
Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification
10:39

Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification

Published on: November 28, 2016

11.4K

Videos de Experimentos Relacionados

Last Updated: Sep 9, 2025

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model
06:03

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model

Published on: June 11, 2020

9.2K
Overexpressing Long Noncoding RNAs Using Gene-activating CRISPR
13:04

Overexpressing Long Noncoding RNAs Using Gene-activating CRISPR

Published on: March 1, 2019

9.0K
Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification
10:39

Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification

Published on: November 28, 2016

11.4K

Área de la Ciencia:

  • Biología molecular
  • Investigación cardiovascular
  • La genética

Sus antecedentes:

  • Las enfermedades cardiovasculares (ECV) son una preocupación importante para la salud mundial, impulsando la necesidad de nuevos enfoques terapéuticos.
  • Los ARN largos no codificantes (ARNlnc) son cada vez más reconocidos como reguladores críticos de la expresión génica en procesos celulares relevantes para la salud y las enfermedades cardiovasculares.

Objetivo del estudio:

  • Revisar las funciones funcionales de los lncRNA en la patogénesis de las enfermedades cardiovasculares.
  • Explorar el potencial de los lncRNA como biomarcadores de diagnóstico y objetivos terapéuticos.
  • Discutir los avances en la terapia génica y las estrategias de administración para tratamientos cardiovasculares basados en lncRNA.

Principales métodos:

  • Revisión de la literatura de estudios sobre la función del lncRNA en las enfermedades cardiovasculares.
  • Análisis de las tecnologías actuales de orientación del ARN (por ejemplo, oligonucleótidos antisenso, siRNA, CRISPR).
  • Evaluación de los sistemas de administración virales y no virales para terapias de lncRNA.

Principales resultados:

  • Los lncRNA están implicados en procesos clave de ECV, incluida la hipertrofia, la fibrosis, la inflamación y la remodelación vascular.
  • Las tecnologías emergentes de orientación de ARN ofrecen posibles vías terapéuticas para las enfermedades cardiovasculares.
  • Sigue habiendo desafíos en la traducción clínica de las terapias basadas en el lncRNA, particularmente en lo que respecta a los métodos de administración.

Conclusiones:

  • Los lncRNAs representan un área prometedora para el desarrollo de nuevas estrategias diagnósticas y terapéuticas para las enfermedades cardiovasculares.
  • Las investigaciones adicionales sobre la biología del lncRNA y la optimización de los sistemas de administración son esenciales para la aplicación clínica.
  • Las terapias basadas en lncRNA tienen el potencial de avanzar significativamente en la medicina cardiovascular.